新股消息 | 德适生物港股IPO及境内未上市股份“全流通”获中国证监会备案

Group 1 - The core point of the news is that Hangzhou Deshi Biotechnology Co., Ltd. plans to issue up to 31.04 million overseas listed ordinary shares and convert 80.88 million domestic unlisted shares into overseas listed shares for trading on the Hong Kong Stock Exchange [1][3]. Group 2 - Deshi Biotechnology focuses on the medical imaging AI industry, with its proprietary iMedImageTM model supporting 19 types of medical imaging modalities and covering over 90% of clinical medical imaging scenarios [3]. - The iMedImageTM model is recognized as the world's largest general-purpose medical imaging base model and the first commercialized cross-modal medical imaging base model [3]. Group 3 - A total of 27 shareholders are involved in the conversion of shares, with the largest shareholder, Song Ning, converting 24,293,507 shares [4][5]. - The total number of shares being converted by all shareholders amounts to 80,880,000 [5].